A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

Completed · Phase 4 · NCT06333860

Conditions: Moderate Plaque Psoriasis

Research payments reported, 2025: $1.8M
U.S. investigators named: 43
Sites paid: 41
Planned or actual enrollment: 393

About the trial

Sponsor: AbbVie
Tested: Risankizumab (drug), Deucravacitinib (drug)
Dates: Started 2024-05-10; completion 2026-03-19
Results posted: Not yet

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and abdomen). In participants with psoriasis, certain skin cells multiply much faster and the skin can develop rough patches that may be red or white with scales. There are many types of psoriasis, but plaque psoriasis is the most common. The exact cause of psoriasis is unknown, but researchers think it may be caused by the body's immune system not working properly. This study is designed to enroll 336 participants 18 years of age and older with have been diagnosed with moderate chronic plaque psoriasis for at least 6 months prior to Baseline (Day…

From ClinicalTrials.gov, last updated 2026-04-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $1.8M in research payments for this study in 2025 (441 payments).

Products named: Skyrizi

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it